Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Promising results found for an autologous melanoma cancer vaccine

March 2, 2004

SGN-30 receives orphan drug designation for T-cell lymphomas

March 1, 2004

Micromet and Boehringer Ingelheim collaborate on MT-201 manufacturing

Feb. 27, 2004

Seattle Genetics and Abbott sign manufacturing agreement for SGN-30

Feb. 26, 2004

Enrollment scheduled to conclude in pivotal MyVax trial

Feb. 23, 2004

Harvard Group to acquire assets of NexTherapeutics; IND anticipated for NXT-211

Feb. 20, 2004

New phase II study for MT-201 in prostate cancer

Feb. 16, 2004

Transgene updates status of phase II trials of MVA-Muc1-IL2

Feb. 12, 2004

SPA agreement for PRECISE trial with IL13-PE38QQR, program accepted for FDA CMA Pilot 2 program

Feb. 11, 2004

Fourth phase II trial for AMD-3100 underway

Feb. 11, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.